XTX Topco’s AbCellera Biologics ABCL Stock Holding History

XTX Topco’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-192,450	Closed	-$672K	–	4092
2026 Q1	$672K	Sell	192,450 -170,801	-47%	-$615K	0.01%	1760
2025 Q4	$1.24M	Buy	+363,251	New	+$1.62M	0.03%	876
2025 Q3	–	Sell	-66,444	Closed	-$228K	–	2480
2025 Q2	$228K	Buy	66,444 +21,191	+47%	+$52.7K	0.01%	1621
2025 Q1	$101K	Sell	45,253 -46,501	-51%	-$133K	0.01%	1864
2024 Q4	$269K	Buy	+91,754	New	+$256K	0.02%	1312
2024 Q3	–	Sell	-33,590	Closed	-$99.4K	–	2022
2024 Q2	$99.4K	Buy	+33,590	New	+$127K	0.01%	1422
2023 Q4	–	Sell	-44,331	Closed	-$204K	–	1515
2023 Q3	$204K	Buy	+44,331	New	+$270K	0.03%	1008
2022 Q4	–	Sell	-68,657	Closed	-$679K	–	1073
2022 Q3	$679K	Buy	68,657 +49,780	+264%	+$546K	0.17%	129
2022 Q2	$201K	Buy	18,877 +4,837	+34%	+$41K	0.08%	467
2022 Q1	$137K	Buy	+14,040	New	+$133K	0.06%	473

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

XTX Topco's ABCL Position: Q2 2026 in Review

XTX Topco sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 192,450 shares — an estimated $672K sold.

XTX Topco first reported a position in ABCL in Q1 2022 and held it in 10 quarters. The position peaked at $1.24M in Q4 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

XTX Topco reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 192,450 AbCellera Biologics shares in Q2 2026, an estimated $672K.
XTX Topco first reported a position in AbCellera Biologics in Q1 2022 and held it in 10 quarters.
XTX Topco's AbCellera Biologics position peaked at $1.24M in Q4 2025.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.